Search

Your search keyword '"Maurillo, Luca"' showing total 397 results

Search Constraints

Start Over You searched for: Author "Maurillo, Luca" Remove constraint Author: "Maurillo, Luca" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
397 results on '"Maurillo, Luca"'

Search Results

1. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia

3. MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients

4. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

5. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

7. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

8. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

10. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

11. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

12. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

13. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

15. P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

16. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

18. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

20. Supplementary Figure 3 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

21. Supplementary Table 4 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

22. Supplementary Table 2 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

23. Supplementary Figure 2 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

24. Supplementary Figure 1 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

25. Supplementary Data from Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

26. Supplementary Table 3 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

27. Supplementary Table 1 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

28. Supplementary Table 5 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

29. Acute leukemia diagnosis during the COVID-19 pandemic

30. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

31. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

33. FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS.

36. Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience

37. Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

38. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

39. The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

40. Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

41. Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment

42. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

43. Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma

44. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study

45. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy

47. Erratum:Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (HemaSphere (2022) 6:1 (e676) DOI: 10.1097/HS9.0000000000000676)

48. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

49. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

Catalog

Books, media, physical & digital resources